ACC.17

Researchers presented 10-year cardiovascular disease (CVD) risk and low-density lipoprotein cholesterol (LDL-C) reduction calculations for alirocumab and evolocumab.

Sildenafil, a phosphodiesterase-5 inhibitor (PDE5I), is an approved treatment for pulmonary artery hypertension.

Study authors also assessed the relative risk of death at specific doses vs. no loop diuretic use and among specific loop diuretic doses.

A total of 70% diabetes patients were prescribed a statin. Men and women received similarly intensive statins, however, significant differences were seen based on ethnicity; with nonwhite patients receiving significantly less intensive statins.

The researchers were able to determine hospitalization risk for composite CV outcomes (myocardial infarction (MI), congestive heart failure (CHF), stroke and angina) as well as risk for individual components.

The researchers conducted and extensive literature search (1945-2014) for randomized, controlled trials that compared anti-anginal drug efficacy for managing stable angina.

Jan Steffel, from the TIMI Study Group, Boston, MA, and colleagues presented on the safety of edoxaban in the context of atrial fibrillation (AF) ablation.